{"entity":{"id":"nct06617416","kind":"trial","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","aka":[],"tldr":"A phase 3 trial of Cadonilimab, Sugemalimab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.","summary":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC is a phase 3 interventional study registered as NCT06617416 by Akeso, with 560 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-10-28. Interventions recorded: Cadonilimab (AK104), Sugemalimab. Conditions listed: NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06617416","url":"https://clinicaltrials.gov/study/NCT06617416"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cadonilimab","sugemalimab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06617416","phase":"3","setting":"A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy","sponsor":"Akeso","enrolled":560,"outcomes":[]},"route":"/trials/nct06617416/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}